ArticleThe World Allergy Organization journal2026
An international scoping review of epidemiologic studies on severe cutaneous adverse reactions.
Article in The World Allergy Organization journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Severe cutaneous adverse reactions (SCARs) are rare but potentially life-threatening drug hypersensitivity reactions. Understanding their epidemiology is critical for improving patient management and informing preventive strategies. Objective: This scoping analysis aims to systematically examine international epidemiologic studies on SCARs, identify geographic patterns and research gaps, and propose directions for future SCAR epidemiology research. Methods: A scoping review of observational studies on SCAR epidemiology published between January 2018 and July 2025 was conducted using PubMed and Embase. Studies were selected based on predefined criteria, with additional hand-searching. Data were extracted on study design, geographic region, data sources, and culprit drug classes. Results: A total of 143 studies were included. The Asia-Pacific region accounted for the largest share (55.9%), followed by Europe (20.9%) and North America (16.8%), with limited representation from Africa and South America. Hospital medical records were the most common data source (54.5%), followed by pharmacovigilance databases (23.1%) and registries (13.3%). Most studies focused on general SCAR epidemiology (58.4%), with others addressing drug-specific (28.7%) and pediatric SCAR (13.3%). Traditional high-risk drugs including anticonvulsants, antigout agents, antibiotics, and antipyretics were reported across all regions, while antituberculosis drugs and traditional medicines were more frequent in the Asia-Pacific. Emerging trends include immune checkpoint inhibitor (ICI)-related SCARs, reflecting the expanding use of novel cancer therapies. Conclusion: Substantial regional disparities were identified in SCAR epidemiology research. These findings highlight the need for standardized data collection, expanded surveillance infrastructure, and region-specific strategies to improve international drug safety as well as SCAR prevention and management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.